bioRxiv Science⌕ Search

Biology subjects

Nolan, K. T.

Publications and source records attributed to Nolan, K. T..

3 recordsLinked to original sources

Allosteric disulfide control of ligand binding and endocytosis of the natural killer cell receptor for HLA-G

Human Leukocyte Antigen (HLA)-G is selectively expressed by fetal trophoblast cells that invade maternal tissue and encounter maternal natural killer (NK) cells early in pregnancy. In NK cells, the endosomal receptor KIR2DL4 responds to soluble HLA-G by inducing a broad transcriptional program to support placental development. Structural features of KIR2DL4 that control ligand binding and endocytosis are unclear. Random mutagenesis revealed that three cysteines in the first immunoglobulin domain of KIR2DL4 regulate endocytosis and uptake of HLA-G. We found that the atypical Cys10-Cys28 disulfide bond observed in the KIR2DL4 crystal structure is an allosteric disulfide with potential to switch to a conventional Cys28-Cys74 bond. KIR2DL4 in human cells exists in both disulfide-bonded states, as shown by mass spectrometry analysis. The Cys10-Cys28 bond in a Cys74Ser KIR2DL4 mutant was reduced by protein disulfide isomerase (PDI) in vitro. Inhibition of PDI prevented HLA-G uptake by KIR2DL4 in both transfected 293T cells and primary NK cells. Mutants in the Cys10-Cys28 configuration endocytosed spontaneously but did not bind HLA-G. Conversely, KIR2DL4 with a Cys28-Cys74 bond was at the plasma membrane and responded to soluble HLA-G by endocytosis and transcription of the interferon stimulated gene IFI44L, like wild-type cells. A purified Cys10Leu KIR2DL4 mutant, which exhibited a reduced tendency to oligomerize, bound HLA-G in a peptide dependent manner with an affinity in the low micromolar range. Disulfide switching from the Cys10-Cys28 to the Cys28-Cys74 form correlated with a distant allosteric change, as predicted by AlphaFold, that could reorient a D0 domain loop to facilitate HLA-G binding. Thus, conversion from an inactive state to an HLA-G binding form regulates KIR2DL4 cellular localization and function to promote fetal development.

immunology↗

Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms

Acinetobacter baumannii is a nosocomial pathogen notorious for rapidly acquiring resistance to nearly all antibiotics, including last-line agents. Cefiderocol (FDC) is a novel siderophore cephalosporin antibiotic with in vitro activity against A. baumannii that is now used clinically, but resistance is emerging. There is limited data regarding FDC-containing antibiotic combinations with synergistic activity against A. baumannii, which may increase the potency of the drug and reduce resistance development. In this study, we evaluated the activity of FDC alone and in combination with other antibiotics against 21 extensively drug-resistant (XDR) and pandrug-resistant (PDR) A. baumannii clinical isolates. FDC possesses strong in vitro activity and was highly effective in combination with ceftazidime-avibactam (CAZ-AVI) and sulbactam-durlobactam (SUL-DUR), as well as amikacin, doxycycline, and sulbactam. We also identified several FDC-containing combinations effective against a metallo-{beta}-lactamase (MBL)-producing strain. Previously, we performed whole genome sequencing on selected strains in our collection, allowing for the identification of resistance genes and mechanisms associated with susceptibility patterns and synergy outcomes. These findings highlight promising FDC-based combinations for treating highly drug-resistant A. baumannii infections and provide insight into the genetic basis of FDC resistance and response. Author SummaryAcinetobacter baumannii is a frequent cause of hospital-acquired pneumonia, and bloodstream and wound infections in vulnerable populations, such as those who are critically ill or immunocompromised. Infections caused by A. baumannii are a growing problem in hospitals around the world, especially because of increasing resistance to almost all available antibiotics. Physicians have few treatment options available, which leads to high mortality rates. One newer antibiotic, cefiderocol, has shown promise against these infections, but resistance to this drug is already emerging. In our study, we looked for combinations of cefiderocol with other traditional and newly available antibiotics that work better together than alone. We tested these combinations against over 20 highly drug-resistant strains isolated from patients, including one strain that produces a strong resistance enzyme called NDM-1. We found that pairing cefiderocol with certain drugs, especially ceftazidime-avibactam, sulbactam-durlobactam, amikacin, and doxycycline, often worked significantly better than using cefiderocol alone. These combinations were able to prevent the growth of even the most resistant strains in our collection. Our work highlights new potential treatment options that physicians may use in the future to help patients with these dangerous, life-threatening infections, especially when standard antibiotics are no longer effective.

microbiology↗

Molecular characterization of the archaic HLA-B*73:01 allele reveals presentation of a unique peptidome and skewed engagement by KIR2DL2

HLA class I alleles of archaic origin may have been retained in modern humans because they provide immunity against diseases to which archaic humans had evolved resistance. According to this model, archaic introgressed alleles were somehow distinct from those that evolved in African populations. Here we show that HLA-B*73:01, a rare allotype with putative archaic origins, has a relatively rare peptide binding motif with an unusually long-tailed peptide length distribution. We also find that HLA-B*73:01 combines a restricted and unique peptidome with high-cell surface expression, characteristics that make it well-suited to combat one or a number of closely-related pathogens. Furthermore, a crystal structure of HLA-B*73:01 in complex with KIR2DL2 highlights differences from previously solved structures with HLA-C molecules. These molecular characteristics distinguish HLA-B*73:01 from other HLA class I alleles previously investigated and may have provided early modern human migrants that inherited this allele with a selective advantage as they colonized Europe and Asia.

biochemistry↗